For research use only. Not for therapeutic Use.
SR12418 is a REV-ERB-specific synthetic ligand with IC50s of 68 nM and 119 nM for REV-ERBα and REV-ERBβ, respectively. SR12418 can be used in experimental autoimmune encephalomyelitis (EAE) and colitis research[1][2].
SR12418 (5 μM; 96 h) inhibits the growth of TH17 cells[1].
SR12418 (5 and 10 μM; 4 d) inhibits cell differentiation under TH17 polarizing conditions[1].
SR12418 (intraperitoneal injection; 50 mg/kg; twice a day) suppresses the development and severity of experimental autoimmune encephalomyelitis[1].
SR12418 (intraperitoneal injection; 50 mg/kg; twice a day; begin at day 18 post-immunization) shows effects in intervention studies of relapsing-remitting experimental autoimmune encephalomyelitis[1].
Catalog Number | I042889 |
CAS Number | 1801185-08-9 |
Synonyms | [(3S)-6-fluoro-3-[[4-[(2-methylpropan-2-yl)oxy]phenoxy]methyl]-3,4-dihydro-1H-isoquinolin-2-yl]-naphthalen-1-ylmethanone |
Molecular Formula | C31H30FNO3 |
Purity | ≥95% |
InChI | InChI=1S/C31H30FNO3/c1-31(2,3)36-27-15-13-26(14-16-27)35-20-25-18-23-17-24(32)12-11-22(23)19-33(25)30(34)29-10-6-8-21-7-4-5-9-28(21)29/h4-17,25H,18-20H2,1-3H3/t25-/m0/s1 |
InChIKey | JIWBEKKHQWSDNN-VWLOTQADSA-N |
SMILES | CC(C)(C)OC1=CC=C(C=C1)OCC2CC3=C(CN2C(=O)C4=CC=CC5=CC=CC=C54)C=CC(=C3)F |
Reference | [1]. Mohammed Amir, et al. REV-ERBα Regulates TH17 Cell Development and Autoimmunity. Cell Rep. 2018 Dec 26;25(13):3733-3749.e8. [2]. Shuai Wang, et al. Targeting REV-ERBα for therapeutic purposes: promises and challenges. Theranostics. 2020 Mar 4;10(9):4168-4182. |